Trial PaperAnxiety DisordersDepressive DisordersMajor Depressive Disorder (MDD)Ketamine

Trial of Ketamine Masked by Surgical Anesthesia in Depressed Patients

This triple-masked, randomised, placebo-controlled trial (n=40) of adults with major depressive disorder (MDD) found no short-term effect on depression severity (measured by MADRS) after a single dose of intravenous ketamine (35mg/70kg) compared to placebo (saline) during anaesthesia for routine surgery.

Authors

  • Boris Heifets
  • Alan Schatzberg

Published

Nature Mental Health
individual Study

Abstract

Background

Ketamine may have antidepressant properties, but its acute psychoactive effects complicate successful masking in placebo-controlled trials.

Methods

In a triple-masked, randomized, placebo-controlled trial, 40 adult patients with major depressive disorder were randomized to a single infusion of ketamine (0.5 mg/kg) or placebo (saline) during anesthesia for routine surgery. The primary outcome was depression severity measured by the Montgomery-Åsberg Depression Rating Scale (MADRS) at 1, 2, and 3 days post-infusion. The secondary outcome was the proportion of participants with clinical response (≥50% reduction in MADRS scores) at 1, 2, and 3 days post-infusion. After all follow-up visits, participants were asked to guess which intervention they received.

Results

Mean MADRS scores did not differ between groups at screening or pre-infusion baseline. The mixed-effects model showed no evidence of effect of group assignment on post-infusion MADRS scores at 1 to 3 days post-infusion (-5.82, 95% CI -13.3 to 1.64, p=0.13). Clinical response rates were similar between groups (60% versus 50% on day 1) and comparable to previous studies of ketamine in depressed populations. Secondary and exploratory outcomes found no evidence of benefit for ketamine. 36.8% of participants guessed their treatment assignment correctly; both groups allocated their guesses in similar proportions.

Conclusion

A single dose of intravenous ketamine compared to placebo has no short-term effect on the severity of depression symptoms in adults with major depressive disorder. This trial successfully masked treatment allocation in moderate-to-severely depressed patients using surgical anesthesia. While it is impractical to use surgical anesthesia for most placebo-controlled trials, future studies of novel antidepressants with acute psychoactive effects should make efforts to fully mask treatment assignment in order to minimize subject-expectancy bias. (ClinicalTrials.gov number, NCT03861988)

Available with Blossom Pro

Research Summary of 'Trial of Ketamine Masked by Surgical Anesthesia in Depressed Patients'

Introduction

Ketamine is a dissociative anaesthetic that has shown rapid-acting antidepressant effects in patients with major depressive disorder (MDD), including treatment-resistant cases. Prior randomised trials using a single intravenous infusion of 0.5 mg/kg report rapid therapeutic onset and measurable response and remission rates within 24 hours. However, the drug’s obvious acute psychoactive effects make participant masking difficult in placebo-controlled trials, creating a risk of subject-expectancy bias that could inflate apparent treatment effects. This concern applies broadly to other fast-acting psychoactive therapeutics as well. Lii and colleagues designed a randomised, triple-masked, placebo-controlled trial that used routine surgical anaesthesia to conceal administration of ketamine or saline, with the primary aim of determining whether a single 0.5 mg/kg infusion of ketamine given during maintenance anaesthesia produces greater short-term antidepressant effects than placebo. The hypothesis was that ketamine would reduce depressive symptoms more than inert saline within the first 3 days post-infusion in adults with moderate-to-severe MDD. The study therefore addresses both efficacy and the feasibility of rigorous masking in ketamine trials.

Expert Research Summaries

Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.

Full Text PDF

Full Paper PDF

Pro members can view the original manuscript directly in the browser.

Study Details

References (12)

Papers cited by this study that are also in Blossom

Antidepressant effects of ketamine in depressed patients

Berman, R. M., Cappiello, A., Anand, A. et al. · Biological Psychiatry (2000)

Great Expectations: Recommendations for improving the methodological rigor of psychedelic clinical trials

Aday, J. S., Heifets, B. D., Pratscher, S. D. et al. · Psychopharmacology (2021)

A phase 2 trial of inhaled nitrous oxide for treatment-resistant major depression

Nagele, P., Palanca, B. J., Gott, B. et al. · Science Translational Medicine (2021)

76 cited
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial

Murrough, J. W., Iosifescu, D. V., Chang, L. C. et al. · American Journal of Psychiatry (2013)

Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression

Sos, P., Klirova, M., Novák, T. et al. · Neuropsychiatric Disease And Treatment (2013)

A consensus statement on the use of ketamine in the treatment of mood disorders

Sanacora, G., Frye, M. A., McDonald, W. et al. · JAMA Psychiatry (2017)

470 cited
Show all 12 references
Nitrous Oxide for Treatment-Resistant Major Depression: a Proof-of-Concept Trial

Nagele, P., Duma, A., Kopec, M. et al. · Biological Psychiatry (2015)

Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression

Jesus‐Nunes, A. P., Leal, G. C., Correia‐Melo, F. S. et al. · Human Psychopharmacology (2022)

31 cited

Cited By (1)

Papers in Blossom that reference this study

Unique Psychological Mechanisms Underlying Psilocybin Therapy Versus Escitalopram Treatment in the Treatment of Major Depressive Disorder

Weiss, B., Leor Roseman, •., Giribaldi, B. et al. · International Journal of Mental Health and Addiction (2024)

Your Personal Research Library

Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.